BRPI0413587A - usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença - Google Patents
usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doençaInfo
- Publication number
- BRPI0413587A BRPI0413587A BRPI0413587-3A BRPI0413587A BRPI0413587A BR PI0413587 A BRPI0413587 A BR PI0413587A BR PI0413587 A BRPI0413587 A BR PI0413587A BR PI0413587 A BRPI0413587 A BR PI0413587A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- disorders
- disorder
- glyt
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 3
- 208000020401 Depressive disease Diseases 0.000 abstract 2
- 229940123454 Glucose transporter 1 inhibitor Drugs 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 abstract 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 abstract 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 abstract 1
- 208000026345 acute stress disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000024732 dysthymic disease Diseases 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019899 phobic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USOS DE UM COMPOSTO E DE UM INIBIDOR DE GlyT-1, COMPOSIçãO FARMACêUTICA, KIT, E, MéTODO PARA O TRATAMENTO DE DOENçA". A presente invenção diz respeito ao uso de um composto, que é um inibidor de recaptação de serotonina, e um composto, que é um inibidor de GlyT-1 para a preparação de uma composição farmacêutica para o tratamento de depressão, distúrbios de ansiedade e outros distúrbios afetivos. Em particular a presente invenção diz respeito ao tratamento de depressão, distúrbios de ansiedade e outros distúrbios afetivos, tais como distúrbio de ansiedade generalizado, ansiedade por pânico, distúrbio obsessivo compulsivo, distúrbio de estresse agudo, distúrbio de estresse pós traumático e distúrbio de ansiedade social, distúrbios de alimentação tais como bulimia, anorexia e obesidade, fobias, distimia, síndrome pré-menstrual, distúrbios cognitivos, distúrbios de controle de impulso, distúrbio de hiperatividade com déficit de atenção, abuso de droga ou qualquer outro distúrbio responsivo aos inibidores de recaptação de serotonina. A presente invenção também diz respeito a uma composição farmacêutica compreendendo um inibidor de recaptação de serotonina, e um inibidor de GlyT-1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49673803P | 2003-08-21 | 2003-08-21 | |
| DKPA200301198 | 2003-08-21 | ||
| PCT/DK2004/000547 WO2005018676A1 (en) | 2003-08-21 | 2004-08-18 | The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413587A true BRPI0413587A (pt) | 2006-10-17 |
Family
ID=34219531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413587-3A BRPI0413587A (pt) | 2003-08-21 | 2004-08-18 | usos de um composto e de um inibidor de glyt-1, composição farmacêutica, kit, e, método para o tratamento de doença |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060223857A1 (pt) |
| EP (1) | EP1660130A1 (pt) |
| JP (1) | JP2007502785A (pt) |
| KR (1) | KR20060066729A (pt) |
| CN (1) | CN1867358A (pt) |
| AU (1) | AU2004266057A1 (pt) |
| BR (1) | BRPI0413587A (pt) |
| CA (1) | CA2536275A1 (pt) |
| IS (1) | IS8277A (pt) |
| MX (1) | MXPA06002002A (pt) |
| NO (1) | NO20061167L (pt) |
| WO (1) | WO2005018676A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
| US8604080B2 (en) * | 2007-02-14 | 2013-12-10 | W. Louis Cleveland | High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders |
| CN101338337B (zh) * | 2007-07-04 | 2011-11-02 | 北京华安佛医药研究中心有限公司 | 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒 |
| EP2380595A1 (en) | 2010-04-19 | 2011-10-26 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000501707A (ja) * | 1995-12-07 | 2000-02-15 | ジャビット，ダニエル・シー | グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置 |
| US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
| CZ294348B6 (cs) * | 1996-05-31 | 2004-12-15 | Allelix Neuroscience Inc. | Substituovaný derivát glycinu a farmaceutický prostředek s jeho obsahem |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| GB2336534A (en) * | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
| DOP2001000189A (es) * | 2000-06-30 | 2002-03-30 | Pfizer Prod Inc | Benzofenonas y sulfonas como inhibidores de la captación de glicina |
| CZ2003396A3 (cs) * | 2000-07-21 | 2003-05-14 | H. Lundbeck A/S | Inhibitory transportu glycinu |
| CN100457738C (zh) * | 2001-12-20 | 2009-02-04 | H·隆德贝克有限公司 | 芳氧基苯基和芳硫基苯基衍生物 |
| US20050288355A1 (en) * | 2002-06-20 | 2005-12-29 | Arne Mork | Combination therapy wherein a serotonin reuptake inhibitor is used |
| MXPA05012493A (es) * | 2003-05-27 | 2006-05-25 | Forest Laboratories | Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo. |
-
2004
- 2004-08-18 KR KR1020067003210A patent/KR20060066729A/ko not_active Withdrawn
- 2004-08-18 EP EP04739042A patent/EP1660130A1/en not_active Withdrawn
- 2004-08-18 WO PCT/DK2004/000547 patent/WO2005018676A1/en not_active Ceased
- 2004-08-18 JP JP2006523530A patent/JP2007502785A/ja not_active Withdrawn
- 2004-08-18 AU AU2004266057A patent/AU2004266057A1/en not_active Abandoned
- 2004-08-18 BR BRPI0413587-3A patent/BRPI0413587A/pt not_active IP Right Cessation
- 2004-08-18 MX MXPA06002002A patent/MXPA06002002A/es not_active Application Discontinuation
- 2004-08-18 US US10/568,133 patent/US20060223857A1/en not_active Abandoned
- 2004-08-18 CN CNA2004800304533A patent/CN1867358A/zh active Pending
- 2004-08-18 CA CA002536275A patent/CA2536275A1/en not_active Abandoned
-
2006
- 2006-01-31 IS IS8277A patent/IS8277A/is unknown
- 2006-03-13 NO NO20061167A patent/NO20061167L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005018676A1 (en) | 2005-03-03 |
| NO20061167L (no) | 2006-03-13 |
| CA2536275A1 (en) | 2005-03-03 |
| CN1867358A (zh) | 2006-11-22 |
| MXPA06002002A (es) | 2006-05-17 |
| IS8277A (is) | 2006-01-31 |
| US20060223857A1 (en) | 2006-10-05 |
| JP2007502785A (ja) | 2007-02-15 |
| AU2004266057A1 (en) | 2005-03-03 |
| EP1660130A1 (en) | 2006-05-31 |
| KR20060066729A (ko) | 2006-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208283A (pt) | Uso de escitaloprama, e, composição farmacêutica | |
| BR0316535A (pt) | Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina | |
| BRPI0212733B8 (pt) | composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo | |
| BR0311503A (pt) | Uso de um composto, uso de um agonista parcial, agonista inverso, ou antagonista de receptor de gabab, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto | |
| ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
| JP2007513052A5 (pt) | ||
| BRPI0411176A (pt) | combinação farmacêutica consistindo de modafinil e outra droga | |
| JP2006514952A5 (pt) | ||
| BR0213949A (pt) | Métodos para o tratamento de depressão e outros distúrbios do snc utilizando metabólitos desmetila e didesmetila de citalopram enanciomericamente enriquecidos | |
| BRPI0512869A (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente | |
| BRPI0415899A (pt) | usos de um composto, e de um antagonista de receptor de h3, agonista inverso ou agonista parcial, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto | |
| SI1392697T1 (en) | Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino 2,3-f)quinoline | |
| BRPI0415454A (pt) | 1,3-dimetilbutilcarboxanilidas para controle de microorganismos indesejáveis | |
| HRP20120713T1 (hr) | Kombinacija analeptičkog modafinila i antidepresiva za liječenje depresije | |
| NO20061167L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon | |
| AR048134A1 (es) | La combinacion de un inhibidor de la recaptacion de serotonina y un antagonista del receptor de la histamina 3, el agonista inverso o el agonista parcial | |
| BRPI0411175A (pt) | combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão | |
| BRPI0508927A (pt) | compostos úteis para o tratamento de doenças | |
| BR0314513A (pt) | Derivados de indolealquil antidepressivo de benzodioxano metilaminas fundidos por heterociclo | |
| BR0314430A (pt) | Derivados de cicloalquilamina antidepressiva dos benzodioxanos fundidos por heterociclo | |
| ATE446299T1 (de) | Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin | |
| BRPI0412268A (pt) | compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a | |
| BR0314431A (pt) | Derivados de piperidina antidepressiva dos benzodioxanos fundidos por heterocilo | |
| EA200001162A1 (ru) | Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола | |
| CO5680440A2 (es) | Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |